DDR gene mutations associated with complete response to chemo in bladder cancer

DELFI liquid biopsy detects liver cancer across diverse international populations, Hopkins-led study finds

Researchers at the Johns Hopkins Kimmel Cancer Center validated an artificial intelligence-powered blood test that accurately detected liver cancer in people from two geographically and biologically distinct populations and also uncovered the underlying biological signals that make the test effective.

August 07, 2026

Vol.52 No.31

Clinical Roundup

Anti-Müllerian hormone may help many women with HR+ breast cancer avoid chemotherapy

Researchers at the University of Kansas Cancer Center, Emory University School of Medicine, and the international Southwest Oncology Group Cancer Research Network have identified a blood biomarker that may help thousands of women with hormone receptor-positive breast cancer avoid unnecessary chemotherapy.

August 07, 2026

Vol.52 No.31

Clinical Roundup

Enfortumab vedotin + pembrolizumab improves survival and reduces recurrence risk in muscle-invasive bladder cancer, phase III trial finds

Researchers have found that a combination of enfortumab vedotin and pembrolizumab helps patients with muscle-invasive bladder cancer live longer while reducing the risk that their cancer will return after surgery, according to the results of an international phase III clinical trial.

July 31, 2026

Vol.52 No.30

Drugs & Targets

EMA approves phase III clinical study of Alpha1H bladder cancer therapy

Alpha1H has received regulatory approval from the European Medicines Agency for its phase III clinical study of the therapy in bladder cancer. The approval represents a milestone for the clinical development of Alpha1H and provides a clear regulatory path toward a potential future marketing application in Europe.

July 24, 2026

Vol.52 No.29

Drugs & Targets

EC approves Padcev + Keytruda as perioperative treatment option for cisplatin-ineligible patients with resectable muscle-invasive bladder cancer

The European Commission granted Marketing Authorization for Padcev (enfortumab vedotin), in combination with Keytruda (pembrolizumab), as neoadjuvant treatment (before surgery) and then continued after radical cystectomy as adjuvant treatment, for adults with resectable muscle-invasive bladder cancer who are ineligible for cisplatin-containing chemotherapy in the European Union.

June 26, 2026

Vol.52 No.25

Clinical Roundup

Catheter with specialized nanosensors could enable earlier detection of bladder cancer, MIT study finds

While treatment is often successful, bladder cancer has one of the highest rates of recurrence of any cancer: Following treatment, about 50% of patients develop tumors again within the next five years. This makes it one of the most expensive cancers for society to treat.

June 05, 2026

Vol.52 No.22

DDR gene mutations associated with complete response to chemo in bladder cancer

YOU MAY BE INTERESTED IN

DELFI liquid biopsy detects liver cancer across diverse international populations, Hopkins-led study finds

Anti-Müllerian hormone may help many women with HR+ breast cancer avoid chemotherapy

Enfortumab vedotin + pembrolizumab improves survival and reduces recurrence risk in muscle-invasive bladder cancer, phase III trial finds

EMA approves phase III clinical study of Alpha1H bladder cancer therapy

EC approves Padcev + Keytruda as perioperative treatment option for cisplatin-ineligible patients with resectable muscle-invasive bladder cancer

Catheter with specialized nanosensors could enable earlier detection of bladder cancer, MIT study finds

Renew today!

Subscriber content

Never miss an issue!

Login